STUDY OF PATIENTS WITH STAGE III BREAST CANCER WHO RECEIVED NEOADJUVANT CHEMOTHERAPY

被引：0
|
作者：
Iwakuma, N. [1 ]
Toh, U. [1 ]
Takahashi, R. [1 ]
Mishima, M. [1 ]
Takenaka, M. [1 ]
Koura, K. [1 ]
Fujii, T. [1 ]
Shirouzu, K. [1 ]
机构：
[1] Kurume Univ, Sch Med, Kurume, Fukuoka 830, Japan
来源：
BREAST | 2013年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S102 / S102
页数：1
相关论文
共 50 条
  • [1] Prognostic role of EGFR in stage II or III breast cancer patients who received neoadjuvant chemotherapy.
    Keam, B.
    Kim, H-J
    Oh, D-Y
    Lee, S-H
    Kim, D-W
    Han, W.
    Im, S-A
    Kim, T-Y
    Park, IAe
    Noh, D-Y
    Heo, D. S.
    Bang, Y-J
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S93 - S93
  • [2] Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy
    Kim, Hyori
    Youk, Jeonghwan
    Yang, Yaewon
    Kim, Tae-Yong
    Min, Ahrum
    Ham, Hye-Seon
    Cho, Seongcheol
    Lee, Kyung-Hun
    Keam, Bhumsuk
    Han, Sae-Won
    Oh, Do-Youn
    Ryu, Han Suk
    Han, Wonshik
    Park, In Ae
    Kim, Tae-You
    Noh, Dong-Young
    Im, Seock-Ah
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (03) : 707 - 714
  • [3] Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy
    Hyori Kim
    Jeonghwan Youk
    Yaewon Yang
    Tae-Yong Kim
    Ahrum Min
    Hye-Seon Ham
    Seongcheol Cho
    Kyung-Hun Lee
    Bhumsuk Keam
    Sae-Won Han
    Do-Youn Oh
    Han Suk Ryu
    Wonshik Han
    In Ae Park
    Tae-You Kim
    Dong-Young Noh
    Seock-Ah Im
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 707 - 714
  • [4] Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy
    Wu, San-Gang
    Li, Qun
    Zhou, Juan
    Sun, Jia-Yuan
    Li, Feng-Yan
    Lin, Qin
    Lin, Huan-Xin
    Gaun, Xun-Xing
    He, Zhen-Yu
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 757 - 764
  • [5] Prognostic factors in patients with operable breast cancer who received neoadjuvant chemotherapy
    Horiguchi, J.
    Takata, D.
    Nagaoka, R.
    Fujii, T.
    Sato, A.
    Tokiniwa, H.
    Higuchi, T.
    Uchida, S.
    Tsuboi, M.
    Yajima, R.
    Kikuchi, M.
    Ino, Y.
    Oyama, T.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S94 - S94
  • [6] Neoadjuvant chemotherapy in stage III breast cancer
    Alassas, M
    Chu, QY
    Burton, G
    Ampil, F
    Mizell, J
    Li, BD
    AMERICAN SURGEON, 2005, 71 (06) : 487 - 492
  • [7] Prognostic value of non-alcoholic fatty liver disease in stage II/III breast cancer patients who received neoadjuvant chemotherapy
    Yang, Y.
    Lee, K-H
    Kim, T-Y
    Han, S-W
    Oh, D-Y
    Kim, T-Y
    Han, W.
    Moon, H-G
    Park, I. A.
    Noh, D-Y
    Im, S-A
    CANCER RESEARCH, 2016, 76
  • [8] Clinical relevance of host immunity in patients with breast cancer who received neoadjuvant chemotherapy
    Bae, Soong June
    Ji, Jung Hwan
    Chu, Chihhao
    Cha, Yoon Jin
    Kim, Jee Hung
    Ahn, Sung Gwe
    Jeong, Joon
    CANCER RESEARCH, 2022, 82 (04)
  • [9] Circulating tumour cells in patients with operable breast cancer who received neoadjuvant chemotherapy
    Horiguchi, J.
    Takata, D.
    Rokutanda, N.
    Nagaoka, R.
    Sato, A.
    Tokiniwa, H.
    Uchida, S.
    Ogino, M.
    Iino, Y.
    Takeyoshi, I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S53 - S54
  • [10] Neoadjuvant chemotherapy for stage III primary breast cancer
    BarrettLee, PJ
    McLaren, DB
    Keen, CW
    Webster, D
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 62 - 62
12345